Barclays analyst Balaji Prasad lowered the firm’s price target on Viatris to $15 from $16 and keeps an Overweight rating on the shares. The company is "marching toward the final phase of its transition," the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VTRS:
- Viatris call volume above normal and directionally bullish
- Viatris upgraded to Buy at Jefferies on increased visibility
- Viatris upgraded to Buy from Hold at Jefferies
- Viatris put volume heavy and directionally bearish
- Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences, Establishing New Viatris Eye Care Division